HomeShop PlansHow It WorksBlogAtlas
For OrganizationsOverviewEmployersHealth PlansHealth Partners
SupportContact Us

For Carriers & Health Plans

Real-Time View of Population Health, Outcomes and GLP‑1 Efficacy at Scale

For the first time, health plans can see exactly how their population is responding in real time. Weight management, GLP‑1 programs, women's health. Not 18 months later in a claims report.

Request a Partnership DemoDownload GLP‑1 Cost Management Guide
Backed byGoogleDexcomSamsung
FDA-Cleared OTCHIPAA CompliantDeployed in WeeksPowered by Stelo by Dexcom

Enterprise-Grade

Enterprise-Grade Capabilities Built for Health Plan Partners

Infrastructure, reporting, and contracting designed for the way health plans actually operate.

Plan Outcomes DashboardOverviewCohortsReports
Enrolled
24,180
Activation
86%
GLP‑1 Trend
−14%
Member outcomes · Q3This yearLast year
JulAugSepOctNovDec
Prevention8,420
Optimization5,180
On GLP‑1s6,920
Post-GLP‑13,660

Real-Time Population Analytics Dashboard

Health plan partners receive access to a dedicated population health dashboard, tracking enrollment, CGM sensor activation rates, app engagement, self-reported weight outcomes, and member-reported quality of life metrics. No claims cycle lag. Know what's working in weeks, not years.

Cohort-level reporting includes condition-specific segmentation for PCOS and perimenopause, giving health plans visibility into their women's metabolic health population for the first time.

HIPAA-Compliant Data Infrastructure

All member data is processed and stored in full compliance with HIPAA requirements. Signos does not share identifiable member data with employers or health plans without member consent. Aggregate, de-identified population data is provided in the plan dashboard.

Flexible Partnership & Contracting Models

Signos offers multiple partnership structures to accommodate commercial carriers, Medicare Advantage plans, and Medicaid managed care organizations.

Turnkey Deployment, Live in Weeks

No EHR integration. No claims data feed. No custom tech build required. Signos handles member onboarding, sensor fulfillment, app provisioning, and ongoing support. Your team's lift is minimal.

The Challenge

The Problem Health Plans Can't Ignore

0%

of Americans are metabolically unhealthy, your at-risk member pool is larger than you think

0%

of Americans are overweight or obese, generating $1,861+ in additional annual medical costs per member

$0B+

projected annual US spend on GLP‑1 medications by 2030, creating urgent pressure on pharmacy trend

0 in 3

Americans has prediabetes, and 80% don't know it, a hidden cost that compounds annually

$0

additional annual medical cost per obese employee, multiplied across your entire population

0–5×

higher healthcare costs for members with obesity-related comorbidities vs. metabolically healthy peers

“It's not a motivation problem, it's a guidance problem. 88% of Americans are metabolically unhealthy, and most don't know it. Understanding how your body processes glucose is one of the most impactful things you can do for long-term health.”

William Dixon, MD · Stanford Physician, Diplomate of the American Board of Obesity Medicine

Highest Cost Trend

Cardiometabolic conditions are now the #1 driver of health plan cost trend. And the current approach, waiting until members qualify for GLP‑1s, bariatric surgery, or diabetes management programs, is leaving billions on the table.

GLP‑1 medications are effective for severe obesity, but they address a fraction of your at-risk population, carry significant cost ($12,000–$16,000/year per member), and don't build the metabolic habits required to maintain results after graduation.

The members generating your highest cost trend aren't just those already on specialty medications. They're the 88% who are metabolically unhealthy today, overweight, prediabetic, or showing early signs of metabolic dysfunction, and heading toward expensive interventions without any intervention.

Signos real-time population analytics dashboard

Three gaps health plans tell us they can't solve today:

Coverage gap

GLP‑1 programs reach the highest-acuity members. The 88% who are metabolically unhealthy today have no upstream intervention.

The result

The Solution

The Signos Solution for Carriers & Health Plans

The only FDA-cleared OTC CGM + AI platform built for population-scale metabolic health, from prevention to post-treatment maintenance.

Signos partners with health plans to offer the first FDA-cleared, non-prescription continuous glucose monitoring system as a member benefit. Paired with Signos' proprietary AI, the system gives at-risk members real-time visibility into how their daily choices, food, activity, stress, sleep, affect their metabolism.

The result: measurable behavior change at scale, a reduction in the progression of metabolic disease, and a clear, trackable ROI signal for the health plan.

No prescription required. No complex integration. Deployed in weeks. Works alongside your existing GLP‑1 program, diabetes prevention initiatives, or as a standalone metabolic benefit.

Signos app and Stelo by Dexcom CGM sensor

Why Signos Is Different

Only FDA-Cleared OTC CGM for Weight Management

Signos is the first and only FDA-cleared over-the-counter continuous glucose monitoring system for weight management in the US, a defensible clinical position no competitor can match.

Real-Time Population Data, Not Annual Claims Lag

Employers and health plans get real-time adoption, adherence, and outcomes data, eliminating the 12–18 month claims lag that makes most wellness program ROI impossible to measure in-year.

AI That Works for Every Member's Unique Metabolism

Signos analyzes 100M+ data points per user to deliver personalized, in-the-moment guidance, not generic advice. Every recommendation is specific to that member's glucose response, activity level, and behavior patterns.

Population-Wide Coverage, Not Just GLP‑1 Candidates

Unlike programs that only serve your highest-acuity members, Signos works across your full population: healthy optimizers, overweight/at-risk members, those on GLP‑1s, and those graduating off them.

Prescription-Free, Removes the #1 Adoption Barrier

Because Signos requires no prescription, members can start immediately. No prior auth, no MD visit, no delay. This drives dramatically higher enrollment than prescription-gated programs.

Deploys in Weeks, Not Quarters

Turnkey deployment with no claims integration or EHR connection required. Streamlined contracting means you're offering the benefit before next open enrollment.

Dr. William Dixon, Stanford Physician

What Doctors Wish You Knew

Developed by researchers at:

HARVARDCornellStanfordPRINCETON
88% of Americans are classified as metabolically unhealthy. It's not a motivation problem, it's a guidance problem. Understanding how your body processes glucose is one of the most impactful things you can do to support a healthy weight and better long-term health.
William Dixon, MDStanford Physician, Diplomate of the American Board of Obesity Medicine

Population Coverage

Designed for Every Segment of Your Population

Most metabolic health programs serve one cohort. Signos serves all four, giving health plans a single platform for complete metabolic coverage, from prevention to post-treatment maintenance.

01 · Prevention

Metabolically At-Risk Members

Overweight, prediabetic, or showing early metabolic dysfunction. Signos intervenes before the condition progresses, reducing your future drug trend.

02 · Optimization

Healthy Members

Members interested in optimizing energy, weight, and performance. Drives benefit engagement and satisfaction. Low cost, high perceived value.

03 · Active Treatment

Members on GLP‑1s

Signos runs alongside GLP‑1 programs to build the behavioral habits pharmaceutical intervention alone cannot create. Improves outcomes. Reduces regain risk.

04 · Post-GLP‑1

GLP‑1 Graduates

The fastest-growing segment. Members who've completed GLP‑1 therapy need behavioral support to maintain results. Signos is the only scalable solution for this cohort.

Also built for high-impact condition cohorts

Women's Metabolic Health — PCOS & Perimenopause

Hormonal shifts fundamentally alter how women metabolize glucose, yet most metabolic health programs are built around male physiology. Signos surfaces the real-time glucose data that makes the difference for women with PCOS, women navigating perimenopause, and women whose weight and energy are being driven by hormonal metabolic dysfunction that claims data never captures.

For health plans, this represents a high-cost, underserved cohort with measurable intervention opportunity and a benefit differentiation story your members will notice.

How It Works For Health Plans

From Contract to Real-Time Outcomes

Five steps. Weeks, not quarters. Swipe through the partnership journey, from first conversation to ongoing population insights.

Step 01 · Partner

Partner

Signos works directly with your benefits or population health team. Streamlined contracting, legal, compliance, and procurement designed for health plan timelines.

Step 02 · Deploy

Deploy

No EHR integration required. No claims feed, no custom tech build. Members receive the Stelo by Dexcom CGM sensor and access to the Signos AI app. Rollout in weeks, not quarters.

Step 03 · Engage

Engage

Members apply a small, discreet CGM sensor and begin receiving real-time glucose insights and personalized AI guidance. Average engagement: 7 app sessions per day in month one.

Step 04 · Measure

Measure

You see population-level outcomes in your employer/plan dashboard in real time, adoption rates, adherence, member-reported outcomes, and engagement metrics. No waiting for annual claims.

Step 05 · Optimize

Optimize

Ongoing population health reporting supports your team in identifying which member cohorts are responding best, enabling targeted outreach and continuous program improvement.

01 / 05

ROI & Cost Impact

Measurable ROI, in Real Time

Traditional wellness programs report ROI 12–24 months after deployment, based on lagging claims data. Signos delivers observable outcome signals within the first 30–60 days, member engagement, behavior change indicators, and self-reported clinical improvements.

The financial case for metabolic intervention is well established. The opportunity for health plans is to move that intervention earlier, before members reach the cost threshold of specialty medications, hospitalizations, or chronic disease management programs. With US GLP‑1 spending projected to reach $35B annually by 2030, the financial upside of moving intervention earlier has never been larger.

0%

of Signos members report success in the first month, creating early signal of program ROI

0×

daily app engagement in month one, the highest of any metabolic health platform in this category

$0

annual cost per obese employee, Signos addresses the behaviors driving this cost trend, not just the symptoms

Financial Value Levers

Financial Value Levers for Health Plans

  • Reduced GLP‑1 initiation rate among pre-qualifying members, measurable in 6–12 months
  • Lower prediabetes-to-diabetes progression rates, reducing long-term chronic disease management costs
  • Improved medication adherence and adherence to lifestyle interventions for members already on treatment
  • Reduced ED and urgent care utilization linked to uncontrolled glucose events
  • Higher member satisfaction and retention scores linked to innovative benefit offerings
  • GLP‑1 graduation support, the #1 near-term cost driver for most health plans in 2025–2027

Work with your Signos partnership team to model the ROI scenario specific to your population, GLP‑1 spend, prediabetes prevalence, and behavior change assumptions.

Run Your ROI Model

Complementary Coverage

Works Alongside Your Existing Programs, Not Instead of Them

Signos is not a replacement for GLP‑1 programs, bariatric benefits, or diabetes management platforms. It's the metabolic behavior foundation that makes every other intervention work better, and last longer.

Signos app tracking GLP‑1 therapy alongside a GLP‑1 medication vial

Before GLP‑1s

Intervenes with at-risk members who don't yet qualify, slowing or preventing disease progression and drug initiation.

During GLP‑1s

Builds the behavior change habits that GLP‑1 medication alone cannot create, improving outcomes and maximizing the value of your drug spend.

After GLP‑1s

Supports GLP‑1 graduates in maintaining results, reducing the weight regain and health deterioration that leads members back to expensive prescriptions.

Signos works alongside:

  • GLP‑1 prescription programs (Ozempic, Wegovy, Zepbound, Mounjaro)
  • CDC-recognized Diabetes Prevention Programs (DPP)
  • Chronic disease management platforms
  • Employee Assistance Programs (EAPs) with wellness components
  • Employer-sponsored gym and fitness benefits

Partnership Models

The Signos Health Plan Partnership

Signos partners with commercial fully-insured and self-insured plans, Medicare Advantage organizations, and Medicaid managed care plans. Partnership structures are customized based on plan type, population size, and program goals, with flexible commercial terms designed for health plan procurement.

Stelo by Dexcom CGM sensor and applicator

What's Included

What Is Included in the Plan Partnership

  • Real-time population analytics dashboard tracking enrollment, activation, and outcomes
  • Flexible commercial models: PMPM, value-based, outcomes-linked, and pilot cohort structures
  • Co-branding and white-label options available for large carriers
  • HIPAA-compliant, SOC 2 Type II infrastructure with BAA available
  • Member onboarding, sensor fulfillment, and app provisioning handled end-to-end by Signos
  • Member communication templates and open enrollment integration support
  • No EHR integration, claims data feed, or custom tech build required
  • Dedicated implementation team. Live in weeks, not quarters.
BAA Available · SOC 2 Type II

Request a Demo

Bring Signos to Your Member Population

An innovative benefit that helps members make smarter lifestyle choices, at scale.

We respect your privacy and protect your data. Review our Privacy Policy—you can unsubscribe at any time.

A Signos member wearing a CGM sensor while working at home

FAQ

Frequently Asked Questions

Yes. Signos is the first and only FDA-cleared over-the-counter continuous glucose monitoring system for weight management in the United States. It is powered by the Stelo by Dexcom biosensor, also FDA-cleared. No prescription is required for members to access the system.

Signos partners directly with health plans through a B2B benefits integration. Members receive a Stelo by Dexcom CGM sensor and access to the Signos AI app, which provides real-time glucose data and personalized metabolic guidance. The health plan receives a population-level analytics dashboard to track adoption, engagement, and outcomes in real time.

No. Signos does not require EHR integration, claims data feeds, or any complex technical infrastructure from the health plan. Deployment is entirely turnkey, Signos handles sensor fulfillment, app provisioning, and member onboarding.

Signos works with commercial fully-insured and self-insured plans, Medicare Advantage organizations, and Medicaid managed care plans. Partnership structures are customized based on plan type, population size, and program goals.

No, and it's important to be clear about this. Signos is complementary to GLP‑1 programs. It serves the broader at-risk population that doesn't yet qualify for GLP‑1s, supports members who are currently on GLP‑1 medications by building behavioral habits, and provides a critical maintenance bridge for members graduating off GLP‑1 therapy.

Signos is designed for adults 18+ who are not on insulin. It is appropriate for: members with prediabetes, members with non-insulin-dependent type 2 diabetes, members on GLP‑1 medications, and members who have recently completed GLP‑1 therapy.

Signos can be deployed as a member benefit in as few as a few weeks from contract execution. There are no complex integrations required. Your implementation team will receive communication templates, member-facing materials, and a dedicated Signos account manager.

Health plans receive access to a real-time population health dashboard tracking enrollment, sensor activation, daily app engagement, and member-reported outcomes. In clinical use, 86% of Signos members report success in the first month. Longer-term metabolic outcomes are tracked through member self-reporting and optional biometric integrations.

Yes. Signos operates in full compliance with HIPAA requirements. Member-identifiable data is not shared with the health plan without member consent. Population-level dashboards use de-identified, aggregate data. A Business Associate Agreement (BAA) is available as part of the partnership contract.

Signos offers flexible commercial models for health plan partners, including per-member-per-month (PMPM) structures and outcomes-linked arrangements. Contact the Signos enterprise team to discuss a partnership model aligned with your population size and program objectives.

More FAQs

Get Started

The Metabolic Benefit Your Members Need. The ROI Your Plan Demands.

Signos partners with health plans to deploy the only FDA-cleared OTC CGM system as a scalable member benefit. From contract to launch in weeks, no complex integrations, no long timelines, no guesswork.

Request a Partnership DemoDownload GLP‑1 Cost Management GuideLearn More About the GLP‑1 Graduation Program